主动脉瓣狭窄合并冠心病患者的经导管主动脉瓣置换联合介入治疗

摘要/Abstract

中图分类号:

R543.3

王墨扬, 陈阳, 叶蕴青, 张洪亮, 吴永健. 主动脉瓣狭窄合并冠心病患者的经导管主动脉瓣置换联合介入治疗[J]. 内科理论与实践, 2021, 16(03): 151-154.

参考文献21

[1]	Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients[J]. N Engl J Med, 2011, 364(23): 2187-2198. doi:10.1056/NEJMoa1103510 URL
[2]	Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients[J]. New Engl J Med, 2016, 374(17): 1609-1620. doi:10.1056/NEJMoa1514616 URL
[3]	Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients[J]. New Engl J Med, 2017, 376(14): 1321-1331. doi:10.1056/NEJMoa1700456 URL
[4]	Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients[J]. N Engl J Med, 2019, 380(18): 1695-1705. doi:10.1056/NEJMoa1814052 URL
[5]	Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients[J]. N Engl J Med, 2019, 380(18): 1706-1715. doi:10.1056/NEJMoa1816885 URL
[6]	Walther T, Hamm CW, Schuler G, et al. Perioperative results and complications in 15,964 transcatheter aortic valve replacements: prospective data from the GARY registry[J]. J Am Coll Cardiol, 2015, 65(20): 2173-2180. doi:10.1016/j.jacc.2015.03.034pmid:25787198
[7]	D’Ascenzo F, Verardi R, Visconti M, et al. Independent impact of extent of coronary artery disease and percutaneous revascularisation on 30-day and one-year mortality after TAVI: a meta-analysis of adjusted observational results[J]. EuroIntervention, 2018, 14(11): e1169-e1177. doi:10.4244/EIJ-D-18-00098 URL
[8]	Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease[J]. Circulation, 2021, 143(5): e72-e227.
[9]	van den Boogert TPW, Vendrik J, Claessen BEPM, et al. CTCA for detection of significant coronary artery disease in routine TAVI work-up[J]. Neth Heart J, 2018, 26(12): 591-599. doi:10.1007/s12471-018-1149-6pmid:30178209
[10]	Faroux L, Guimaraes L, Wintzer-Wehekind J, et al. Coronary artery disease and transcatheter aortic valve replacement[J]. J Am Coll Cardiol, 2019, 74(3): 362-372. doi:10.1016/j.jacc.2019.06.012 URL
[11]	Tarus A, Tinica G, Bacusca A, et al. Coronary revascularization during treatment of severe aortic stenosis[J]. J Cardiac Surg, 2020, 35(8): 2009-2016. doi:10.1111/jocs.14814 URL
[12]	Blumenstein J, Kim WK, Liebetrau C, et al. Challenges of coronary angiography and intervention in patients previously treated by TAVI[J]. Clin Res Cardiol, 2015, 104(8): 632-639. doi:10.1007/s00392-015-0824-5pmid:25720330
[13]	van Rosendael PJ, van der Kley F, Kamperidis V, et al. Timing of staged percutaneous coronary intervention before transcatheter aortic valve implantation[J]. Am J Cardiol, 2015, 115(12): 1726-1732. doi:10.1016/j.amjcard.2015.03.019pmid:25890631
[14]	Singh V, Rodriguez AP, Thakkar B, et al. Comparison of outcomes of transcatheter aortic valve replacement plus percutaneous coronary intervention versus transcatheter aortic valve replacement alone in the United States[J]. Am J Cardiol, 2016, 118(11): 1698-1704. doi:10.1016/j.amjcard.2016.08.048 URL
[15]	Penkalla A, Pasic M, Drews T, et al. Transcatheter aortic valve implantation combined with elective coronary artery stenting: a simultaneous approach[J]. Eur J Cardiothorac Surg, 2015, 47(6): 1083-1089. doi:10.1093/ejcts/ezu339pmid:25217500
[16]	Barbanti M, Todaro D, Costa G, et al. Optimized screening of coronary artery disease with invasive coronary angiography and ad hoc percutaneous coronary intervention during transcatheter aortic valve replacement[J]. Circ Cardiovasc Interv, 2017, 10(8): e005234. doi:10.1161/CIRCINTERVENTIONS.117.005234 URL
[17]	Ribeiro HB, Webb JG, Makkar RR, et al. Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry[J]. J Am Coll Cardiol, 2013, 62(17): 1552-1562. doi:10.1016/j.jacc.2013.07.040 URL
[18]	Rodés-Cabau J, Ribeiro HB. Consolidating the BASILICA technique in TAVI patients at risk of coronary obstruction[J]. EuroIntervention, 2020, 16(8): 617-619. doi:10.4244/EIJV16I8A114pmid:33095163
[19]	Vilalta V, Asmarats L, Ferreira-Neto AN, et al. Incidence, clinical characteristics, and impact of acute coronary syndrome following transcatheter aortic valve replacement[J]. JACC Cardiovasc Interv, 2018, 11(24): 2523-2533. doi:10.1016/j.jcin.2018.09.001 URL
[20]	Mentias A, Desai MY, Saad M, et al. Incidence and outcomes of acute coronary syndrome after transcatheter aortic valve replacement[J]. JACC Cardiovasc Interv, 2020, 13(8): 938-950. doi:10.1016/j.jcin.2019.11.027 URL
[21]	Tang GHL, Zaid S, Fuchs A, et al. Alignment of transcatheter aortic-valve neo-commissures (ALIGN TAVR): impact on final valve orientation and coronary artery overlap[J]. JACC Cardiovasc Interv, 2020, 13(9): 1030-1042. doi:10.1016/j.jcin.2020.02.005 URL

主动脉瓣狭窄合并冠心病患者的经导管主动脉瓣置换联合介入治疗

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献21

相关文章15

编辑推荐

Metrics

本文评价

[1]	胡健, 杨震坤, 闫小响, 杜润, 丁风华, 刘俊.经皮冠状动脉介入术和冠状动脉旁路移植术对80岁以上左前支慢性闭塞患者的疗效比较[J]. 内科理论与实践, 2022, 17(01): 70-72.
[2]	陆浩, 葛雷.慢性完全闭塞病变介入治疗临床研究进展[J]. 内科理论与实践, 2021, 16(03): 145-150.
[3]	钱杰.血管内超声指导冠状动脉左主干介入治疗[J]. 内科理论与实践, 2021, 16(03): 155-160.
[4]	刘晓丽, 马晓腾.CYP2C19基因型与冠心病精准抗血小板治疗[J]. 内科理论与实践, 2021, 16(03): 161-166.
[5]	江磊.主动脉瓣狭窄的治疗[J]. 外科理论与实践, 2019, 24(04): 307-310.
[6]	胡健, 张瑞岩, 杨震坤, 丁风华, 沈卫峰,.血管内超声在无保护左主干病变介入治疗中的应用[J]. 内科理论与实践, 2017, 12(02): 120-122.
[7]	胡健, 张瑞岩, 杨震坤, 丁风华, 沈卫峰,.介入治疗和冠状动脉旁路移植术对高龄无保护左主干病变患者的疗效比较[J]. 内科理论与实践, 2017, 12(01): 46-49.
[8]	席锐, 顾刚, 陶蓉,.经皮冠状动脉介入治疗患者围手术期TnI升高的相关因素分析[J]. 诊断学理论与实践, 2013, 12(02): 175-178.
[9]	何清, 何奔,.肾动脉狭窄的诊断和治疗进展[J]. 内科理论与实践, 2009, 4(06): 511-513.
[10]	何奔,.急性心肌梗死的介入治疗——从临床证据到临床实践[J]. 内科理论与实践, 2009, 4(03): 164-170.
[11]	孙瑜, 卜军, 宋玮, 杜勇平, 金叔宣, 沈节艳, 何奔,.急性心肌梗死患者急诊经皮冠状动脉介入治疗后对比剂肾病的研究[J]. 内科理论与实践, 2009, 4(03): 192-195.
[12]	张娴, 戴嘉,.经皮冠状动脉介入治疗术后ST段回落对急性心肌梗死预后的影响[J]. 内科理论与实践, 2009, 4(03): 212-213.
[13]	何奔, 龚兴荣,.血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂在直接经皮冠状动脉介入治疗中的应用[J]. 内科理论与实践, 2009, 4(03): 234-235.
[14]	马长生,.药物洗脱支架在急性心肌梗死治疗中的应用[J]. 内科理论与实践, 2009, 4(03): 171-174.
[15]	颜红兵, 赵汉军,.远端保护和血栓抽吸装置在急诊经皮冠状动脉介入治疗中的应用[J]. 内科理论与实践, 2009, 4(03): 175-179.